Aclaris Therapeutics Announces $20.0 Million Private Placement Malvern, PA – May 27, 2016 (GLOBE NEWSWIRE) – Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage specialty pharmaceutical company, announced today that it has entered into a stock purchase agreement with a group of institutional accredited investors for the private placement of 1,081,082 shares of common stock at a purchase price of $18.50 per share, yielding expected gross proceeds of $20.0 million. The private placement is expected to close on or about June 2, 2016, subject to the satisfaction of customary closing conditions. The private placement was led by Aisling Capital with participation by additional new and existing investors. Net proceeds from this offering are expected to be used to fund research and development, including new JAK inhibitor programs for androgenetic alopecia (also known as male or female pattern baldness) and vitiligo, as well as ongoing business development. The securities being issued and sold in the private placement have not been registered under the Securities Act of 1933, as amended. Accordingly, these securities may not be offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction. William Blair acted as the lead placement agent for the offering. Guggenheim Securities served as the co-placement agent. | 
